Reports of improved efficacy with panitumumab and cetuximab in patients with wild-type versus mutant or unknown KRAS exon 2 status [8–15] led to the requirement for physicians to determine a patient’s tumor KRAS mutation status prior to starting treatment with EGFR inhibitors. Here, EGFR is linked to neoplasm.